ReviewSeminars in liver disease2013
Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.
Review in Seminars in liver disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it, 178 citations in OpenAlex.
- Review: Metabolic Syndrome in Black South African Women.Ethnicity & disease · 2017Pooled it
- Associations between fatty liver index and asymptomatic intracranial vertebrobasilar stenosis in Chinese population.PloS one · 2017Trial
- Resveratrol alleviates lipid deposition, endoplasmic reticulum stress, inflammation and apoptosis in the livers of large yellow croaker (Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2026Article
- Dysregulated high-density lipoprotein and low-density lipoprotein subfractions increase metabolic dysfunction-associated steatotic liver disease risk: a study of patients across body mass index categories.Frontiers in nutrition · 2026Article
- Metabolic dysfunction‑associated steatotic liver disease: Pathogenesis, model and treatment (Review).International journal of molecular medicine · 2025Review
- Adipose tissue-derived PRXL2A suppresses hepatic lipogenesis in a study with male mice.Nature communications · 2025Article
- Association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): data from the NHANES III (1988-1994).Nutrition & metabolism · 2025Article
- Fenofibrate Treatment Inhibits Very-Low-Density Lipoprotein Transport Vesicle Formation by Reducing Sar1b Protein Expression.International journal of molecular sciences · 2025Article
- Targeting fibroblast growth factor (FGF)-21: a promising strategy for metabolic dysfunction-associated steatotic liver disease treatment.Frontiers in pharmacology · 2025Review
- Effect of water extract of bay laurel (Food & nutrition research · 2025Article
- Association between the atherogenic index of plasma and non-alcoholic fatty liver disease in Korean pregnant women: secondary analysis of a prospective cohort study.Frontiers in nutrition · 2025Article
- Effect ofWorld journal of gastroenterology · 2024Article
- Novel non-HDLc/HDLc ratio for predicting MASLD: a cross-sectional study in a Chinese health screening population.BMC gastroenterology · 2024Article
- Fibrosis-4 Score Is Associated with Mortality in Hemodialysis Patients with Chronic Viral Hepatitis: A Retrospective Study.Diagnostics (Basel, Switzerland) · 2024Article
- Acetate attenuates hypothalamic pyroptosis in experimentally induced polycystic ovarian syndrome.BMC research notes · 2024Article
- Baseline and change in serum lipid and uric acid level over time and incident of nonalcoholic fatty liver disease (NAFLD) in Chinese adults.Scientific reports · 2024Article
- Assessing the impact of concurrent high-fructose and high-saturated fat diets on pediatric metabolic syndrome: A review.World journal of clinical pediatrics · 2024Review
- The anti-hyperlipidemia effect ofHeliyon · 2024Article
- Pharmacologic inhibition of lipogenesis for the treatment of NAFLD.Journal of hepatology · 2024Review
- The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a predictive indicator of CKD risk in NAFLD patients: NHANES 2017-2020.Frontiers in nutrition · 2024Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Cardiovascular disease represents the most common cause of death in patients with nonalcoholic fatty liver disease (NAFLD). Patients with NAFLD exhibit an atherogenic dyslipidemia that is characterized by an increased plasma concentration of triglycerides, reduced concentration of high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) particles that are smaller and more dense than normal. The pathogenesis of NAFLD-associated atherogenic dyslipidemia is multifaceted, but many aspects are attributable to manifestations of insulin resistance. Here the authors review the structure, function, and metabolism of lipoproteins, which are macromolecular particles of lipids and proteins that transport otherwise insoluble triglyceride and cholesterol molecules within the plasma. They provide a current explanation of the metabolic perturbations that are observed in the setting of insulin resistance. An improved understanding of the pathophysiology of atherogenic dyslipidemia would be expected to guide therapies aimed at reducing morbidity and mortality in patients with NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.